Govt on Covishield: No blood clots so far, review on

Tribune News Service

New Delhi, March 13

After nearly 10 countries suspended the use of Serum Institute made AstraZeneca-Oxford University vaccine over blood clots in recipients, India said no serious adverse events had been seen at home following the administration of Covishield but safety reviews are ongoing.

India has so far delivered 2,91,92,547 vaccine doses, majority of them Covishield, and seen 234 adverse events, including 71 deaths post vaccinations.

Read also: Three health workers who received AstraZeneca vaccine in hospital with 'unusual' symptoms, says Norway

None of the adverse events have so far been causally linked to the vaccines.

The government today said post vaccination reviews of Covishield would be undertaken to review safety.

Meanwhile, the WHO yesterday said AstraZeneca was an excellent vaccine and should continue to be used as no evidence was available to suggest otherwise.